Bromergon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bromergon

Property Description
Active ingredient Bromocriptine (as mesilate salt)
Form Oral tablet or capsule
Pharmacological class Dopamine Receptor Agonist; Ergot Alkaloid
General purpose Hormonal balance (prolactin control)
Origin Semisynthetic

What Type of Medicine is Bromergon?

Bromergon is a prescription medication whose active ingredient is bromocriptine (bromocriptine mesilate). It is classified as an ergot derivative and belongs to the larger pharmacological class of dopamine receptor agonists.

This classification means the medicine is chemically derived from substances found in the ergot fungus, making it a semisynthetic alkaloid. Bromocriptine acts by binding to and stimulating dopamine receptors in the body. This action is clinically recognized for its effectiveness in influencing the body's hormonal systems.

What is Bromergon Made Of and What is its Form?

Bromergon is typically manufactured as a solid dosage form, most commonly an oral tablet, which is designed to be taken by mouth. The main active component is the bromocriptine base, supplied as a salt called bromocriptine mesilate.

As a single-entity medicine, it contains only one active drug component. Bromergon is a specific trade name for bromocriptine often used internationally. The tablet also includes inactive ingredients, or excipients (such as lactose and starch), which are necessary to form the tablet structure and ensure the medicine can be absorbed correctly via the oral route of administration.

What is the General Purpose of Bromergon?

The medicine's general purpose is to act as a regulator for certain hormones controlled by the pituitary gland. Bromocriptine works by binding to specific D2 dopamine receptors in the pituitary, which directly inhibits the secretion of the hormone prolactin into the bloodstream.

This action allows the medicine to help normalize prolactin levels, which, when elevated, can cause various issues related to hormonal imbalance. For instance, it is typically used in scenarios where excess prolactin production needs to be safely reduced. As a dopamine agonist, it is used to affect the body's balance of hormones and neurological function.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus page on Bromocriptine
  2. The U.S. National Library of Medicine (NLM)

What side effects are possible with Bromergon?

Possible Side Effects and Safety Information

The safety profile of Bromergon, which contains the active ingredient bromocriptine, is based on data documented in official governmental regulatory sources. Adverse reactions are classified by frequency and associated body systems.

Frequency-Classified Adverse Reactions

The most Common (occurring in 1% to 10% of users) side effects listed in regulatory documents include nausea, vomiting, headache, dizziness, constipation, and nasal congestion. Reactions classified as Uncommon include confusion, hallucinations, dry mouth, and allergic skin reactions.

Serious Adverse Reactions and Safety Constraints

Rare but serious risks are documented, particularly concerning the cardiovascular and pulmonary systems. These include documented cases of cardiac valvulopathy and pulmonary/retroperitoneal fibrosis, which are primarily associated with long-term, high-dose exposure.

A critical safety restriction is the contraindication for its use in postpartum women for the suppression of lactation, due to the documented risk of severe events such as stroke, myocardial infarction, and severe hypertension. The medication is also contraindicated in patients with uncontrolled hypertension or known hypersensitivity to ergot alkaloids.

Safety Patterns and Monitoring

Certain effects, such as dizziness and orthostatic hypotension (low blood pressure upon standing), are noted to be more common during the initiation of therapy or during dose increases. Due to the risk of blood pressure changes, regulatory documents advise blood pressure monitoring particularly during the first day of treatment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for bromocriptine (Bromergon) overdose describes the potential for serious manifestations, which require immediate medical attention.

Documented Overdose Presentations

Regulatory labeling documents specific clinical signs and symptoms that may occur following an overdose. These presentations include severe hypotension, vomiting, nausea, pallor, fainting (syncope), sweating, dizziness, drowsiness, confusion, and hallucinations.

Severe Outcomes and Emergency Action

Serious, life-threatening outcomes reported in the context of high doses or toxicity include seizures, stroke (Cerebrovascular Accident), and acute myocardial infarction. Due to the potential for these severe effects, regulators mandate that immediate medical attention must be sought for any suspected overdose. Patients are directed to contact a Poison Control Center or emergency services immediately.

Supportive Management and Specific Considerations

Treatment is officially defined as symptomatic and supportive, focusing on managing the patient's condition, as no specific antidote is known for bromocriptine overdose. Continuous blood pressure monitoring and observation are required. Regulatory documents note that the overdose profile includes considerations for specific populations, such as reported cases of accidental ingestion by children and a documented risk of serious vascular adverse reactions in postpartum women.

Therapeutic Uses of Bromergon

Quick Facts

  • May assist in managing manifestations of high prolactin levels (hyperprolactinemia).
  • Used in the management of acromegaly, a condition associated with excess growth hormone.
  • Employed as a therapy option to address symptoms of Parkinson’s disease.
  • The quick-release formulation is utilized to help improve blood sugar control in adults with Type 2 diabetes.

Bromergon, which contains the active ingredient bromocriptine, is used to address several clinical areas. The medication may be applied in the management of conditions related to hyperprolactinemia, which involves elevated levels of the hormone prolactin. This includes managing associated symptoms such as abnormal menstrual cycles, nipple discharge, and infertility.

It is also a therapeutic option for individuals with certain prolactin-secreting pituitary tumors (prolactinomas), where it may help decrease tumor size. Additionally, the medication is used in the care of acromegaly, a disorder characterized by excessive growth hormone, with the goal of helping to reduce circulating levels of the hormone. For individuals with Parkinson's disease, Bromergon is used to address and manage movement-related symptoms. Finally, a specialized quick-release formulation is utilized as an adjunct to diet and exercise to help improve glycemic control in adults diagnosed with Type 2 diabetes mellitus.


Eligibility and Restrictions for Use

Bromergon (bromocriptine) eligibility is strictly defined by regulatory documents, focusing primarily on a patient's cardiovascular and physiological status.

Absolute Prohibitions (Contraindications)

The medicine is strictly prohibited for patients with uncontrolled hypertension and individuals with known hypersensitivity to bromocriptine or other ergot alkaloids. It is also contraindicated for patients with specific hypertensive disorders of pregnancy, such as pre-eclampsia. Due to its effect on milk production, it must not be used by nursing women. Contraindications may also apply to patients with a history of severe cardiovascular conditions for non-life-threatening uses.

Age and Condition Restrictions

The safety and efficacy are not established for any approved indication in pediatric patients under 11 years of age. Although use is established for adolescents (16 and older) and documented in children (11-15) for specific tumor treatments, caution is required. Older adult patients (65+) may have greater sensitivity, as regulatory data is insufficient to rule out differential response in this group. Use also requires special consideration in patients with hepatic (liver) or renal (kidney) impairment, as these conditions can alter the body’s clearance of the medicine. Furthermore, routine use for lactation suppression is generally not recommended and is restricted to compelling medical reasons.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Bromergon

Interaction scope Medicinal product categories with documented interactions: Cytochrome P450 3A4 (CYP3A4) inhibitors and inducers; dopamine receptor antagonists; ergot-related drugs; antihypertensive agents; and highly protein-bound therapies. Specific interacting medicines (if explicitly listed): Metoclopramide; phenothiazines, butyrophenones, thioxanthenes (as neuroleptic agents); and sympathomimetic drugs (in specific populations). Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction via CYP3A4 inhibits clearance and increases plasma levels. Pharmacodynamic interaction where antagonists diminish effectiveness. Bromocriptine may increase the unbound fraction of other highly protein-bound therapies. Timing-based interaction rules (if applicable): Concurrent use of ergot-related drugs is not recommended within six hours of bromocriptine dosing. Population-specific interaction notes (if applicable): Patients with hepatic impairment may experience increased plasma levels. Co-administration with sympathomimetics or ergot alkaloids is not recommended for postpartum women due to risk of hypertension. Interaction-related restrictions: Strong CYP3A4 inhibitors must be avoided due to the risk of increased exposure. Alcohol should be avoided as it may exacerbate nervous system side effects.

Interaction classifications (high-level) Interaction severity classification (as defined in official documents): Combinations with strong CYP3A4 inhibitors are formally classified as contraindicated. Use with dopamine receptor antagonists is not recommended. Regulatory basis (EMA / FDA / etc.): The profile is based on the FDA Prescribing Information and EMA/National Health Agency Summary of Product Characteristics. Interaction-context constraints (as defined in official documents): Interactions are constrained by the metabolic capacity of the CYP3A4 enzyme and antagonism at the dopamine receptor.

Resulting interaction structure Official interaction statements:

  • Co-administration with strong CYP3A4 inhibitors is contraindicated due to an increase in bromocriptine plasma concentration.
  • Concomitant use with neuroleptic agents may result in a mutual reduction of therapeutic effectiveness.
  • Bromocriptine may increase the unbound fraction of co-administered highly protein-bound drugs, altering the official exposure levels of those agents.
  • The use of ergot-related drugs should be separated from bromocriptine dosing by at least six hours.
  • The combination with sympathomimetics or ergot alkaloids in postpartum women is not recommended due to risk of severe hypertension.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product's interaction structure primarily through two domains: pharmacokinetic interactions resulting from extensive CYP3A4 metabolism and pharmacodynamic interactions related to its activity as a dopamine receptor agonist. These documented pathways dictate specific combination prohibitions, such as with strong CYP3A4 inhibitors, and mandatory constraints, including the timing separation required for co-administration with other ergot-related drugs.

Mechanism of Action

Bromergon (bromocriptine) functions primarily by engaging the dopamine system to modulate specific neuroendocrine regulation pathways. It acts as a dopamine receptor agonist, initiating a cascade of molecular events that lead to resulting physiological changes within the neuroendocrine system.

Bromergon primarily engages mechanisms involving D2 receptor-mediated signaling by binding to and activating these receptors, predominantly on lactotroph cells in the anterior pituitary gland. This receptor activation initiates an inhibitory intracellular signaling sequence that suppresses the synthesis and release of the hormone prolactin, which results in reduced signaling within specific regulatory pathways.

The drug is relevant in systems where the tuberoinfundibular dopamine pathway dominates endocrine regulation, specifically by mimicking and augmenting the inhibitory dopamine signal on the pituitary. By modifying this key molecular step, Bromergon impacts regulatory processes and is associated with subsequent alterations in circulating hormone levels, which shape the drug’s consequence of reduced prolactin secretion.

Dosage and Administration Information

Bromergon (bromocriptine) is administered exclusively through the oral route, taken as either a tablet or a capsule. The official administration protocol is characterized by a required low-dose initiation followed by a slow, gradual increase, a process known as titration. This method is intended to help establish tolerance and determine the minimum effective maintenance dosage.

The dosing schedule is highly dependent on the condition being addressed. For most uses, such as hyperprolactinemia, treatment begins with a starting dose of 1.25 to 2.5 mg per day. The dose is then increased gradually, typically every two to seven days or weekly. Maintenance doses vary significantly, ranging from approximately 2.5 mg to 30 mg per day for conditions like acromegaly or Parkinson’s disease, though doses may reach up to 100 mg daily in specific circumstances. A separate quick-release formulation, used for Type 2 diabetes, has a maximum dose of 4.8 mg per day.

All formulations are administered with food to minimize common gastrointestinal effects. Furthermore, the quick-release formulation has a specific timing constraint: it must be taken once daily within two hours of waking in the morning. If a dose is missed, it is typically recommended to skip that dose and resume the normal schedule; doses should never be doubled. For older adults, treatment is typically initiated at the lower end of the established dosing range.

Recent Clinical Evidence

Research Evidence Overview of Studies for Bromergon


Evidence for Use in Hyperprolactinemia and Prolactinomas

Bromergon, which contains bromocriptine, was studied for conditions involving elevated prolactin levels (hyperprolactinemia) and for prolactin-secreting pituitary tumors (prolactinomas). The research base includes clinical trials and data that have been used to support its inclusion on regulatory lists, such as the WHO Essential Medicines List.

The research examined various outcomes related to systemic or functional imbalance. Specifically, studies monitored shifts in prolactin levels in the bloodstream. In trials involving prolactinomas, research also explored measurements of the physical dimensions of the tumors. Additionally, studies observed how associated symptoms—like changes to the menstrual cycle or nipple discharge—were recorded in the observed populations during the study periods.

Evidence for Use in Parkinson's Disease and Acromegaly

Bromergon was evaluated in research related to the management of Parkinson's disease. The research describes its evaluation for the management of the condition, focusing on movement-related symptoms and daily activity level. Similarly, for acromegaly, the research describes its evaluation for the management of the condition, focusing on measuring changes in circulating levels of growth hormone in the blood. The findings describe patterns observed in these studies related to symptom and hormone measurements.

Evidence for Use in Type 2 Diabetes Mellitus (Quick-Release Formulation)

The quick-release formulation of Bromergon was evaluated in clinical trials for its role as an adjunct (added) therapy to diet and exercise in adults with Type 2 diabetes mellitus. This research primarily examined short-term measurements of glycemic control (blood sugar levels) in the studied populations.

What is Still Uncertain About Bromergon Research

While a body of research contributes to the broader evidence landscape, there are areas where certainty remains low.

  • The follow-up durations were limited in many of the core studies, meaning the data available on long-term outcomes are not well characterized.
  • Data for certain groups remain insufficient. For instance, the research summaries do not fully establish the extent of dedicated evidence available for specific subgroups, such as older adults or individuals with pre-existing, significant medical conditions beyond the primary condition being studied.

Key Studies & References

  1. Bromocriptine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Bromergon (FAQ)

Q: Does Bromergon interact with common pain relievers like ibuprofen or aspirin?

Official documents indicate that Bromergon is highly bound to proteins in the blood. The prescribing information states that using Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, carries a risk of serious gastrointestinal events. Therefore, the potential for interactions with these types of medicines is noted.


Q: How quickly can I expect to notice any change after starting Bromergon?

Studies examining the drug’s effects on hormone levels indicate that a reduction in serum prolactin can be observed within 2 hours of taking a dose, with the maximum effect generally achieved around 8 hours. For indications related to growth hormone, concentration reductions may be observed within 1 to 2 hours.


Q: Can Bromergon be taken if I am also taking vitamins or herbal supplements?

Official documentation recommends informing healthcare providers about all concomitant therapies. This includes all medicines, vitamins, and herbal supplements, as regulatory bodies note their potential for interactions with Bromergon.


Q: Is there a risk of withdrawal symptoms if Bromergon is stopped suddenly?

Regulatory guidance warns against discontinuing the medication suddenly or without medical direction. Abrupt cessation may result in withdrawal symptoms, which have been reported to include anxiety, depression, confusion, fever, or muscle stiffness.


Q: Can men use Bromergon for any condition?

The medication is indicated for conditions such as Parkinson’s disease, acromegaly, and dysfunctions associated with high prolactin levels. Since these conditions are relevant to all patients, the approved indications are not gender-exclusive.


Q: How long does the effect of a single Bromergon dose typically last?

Pharmacokinetic data indicates that the half-life of the drug is generally between 2 and 8 hours. The effect of a single dose on regulating serum prolactin levels may last up to 8 hours.


Q: Are there any specific foods I should avoid while on Bromergon?

Official documents require that the medication is taken with food to help minimize gastrointestinal side effects. To help manage common symptoms like nausea, some patient resources suggest eating simple meals and avoiding rich or spicy foods.


Q: Is it true that Bromergon can cause changes in mood or sleep?

Yes, official sources list changes in mental status and mood as possible side effects. These reactions have been reported to include confusion, hallucinations, agitation, and trouble sleeping (insomnia).


Q: Does Bromergon affect vision or cause eye problems?

Blurred or impaired vision is listed in official documents as a possible serious side effect. Vision changes are considered serious and require prompt medical assessment.


Q: What should I do if a side effect of Bromergon is bothering me?

General guidance recommends consulting with a healthcare provider or pharmacist if any side effects are severe, persistent, or become bothersome. Serious side effects, such as chest pain or breathing problems, require immediate emergency medical help.


Q: How often do people usually need to follow up with their doctor while on Bromergon?

Regulatory guidance states that follow-up and monitoring are necessary. Monitoring blood pressure is essential, especially during the initial phase of treatment and following any dose increases. Long-term use may also require periodic cardiac assessment.


Q: Is Bromergon a controlled substance?

No. According to the drug classification systems, the medication is not classified as a controlled substance under the Controlled Substances Act (CSA) schedule.


Q: What kind of studies have been done to show how Bromergon works?

The basis for the drug's approved uses is supported by evidence from clinical data. This evidence includes well-controlled trials in adults and additional supporting data in limited pediatric populations.


Q: Is Bromergon known to cause weight changes (gain or loss)?

Weight changes, specifically unexplained weight loss or significant weight gain, have been reported in official documents as possible symptoms. Any noticeable weight change is a symptom that should be discussed with a healthcare professional.


Q: Do I need a special diet while using Bromergon?

The official product information states the medicine must be taken with food. Beyond this, some guidance recommends maintaining a well-balanced diet and consuming enough water to help manage common issues like constipation.


Q: What is the general duration of treatment with Bromergon for different conditions?

The necessary duration of treatment is highly individualized and determined by the specific condition. For some hyperprolactinemia-related conditions, a therapeutic response is often observed within 8 to 12 weeks of starting treatment.


Q: Are there any official warnings about driving or operating machinery while taking Bromergon?

Official safety warnings state that due to the potential for dizziness or suddenly falling asleep, driving or operating heavy machinery should be avoided until a patient is certain how the drug affects them.


Q: If I feel better, can I stop taking Bromergon?

Official patient information explicitly states the medication should not be stopped suddenly without consulting a doctor first. Stopping abruptly may lead to the return of the underlying condition or trigger withdrawal symptoms.


Q: Is Bromergon prescribed for headaches or migraines?

The medication is not indicated for the treatment of typical headaches or migraines. For some formulations, official warnings state that the drug is contraindicated in patients who have a history of fainting episodes with migraine headaches.


Q: What is the purpose of the warning label regarding specific mental health conditions with Bromergon?

The warning label is intended to address the risk of developing unusual or compulsive behaviors. This includes strong, uncontrolled urges such as increased desire for gambling, sex, spending money, or binge-eating.


Q: Can I take other medicines for nausea while on Bromergon?

Due to interaction potential, discussing the use of any anti-nausea medicines is necessary with a healthcare provider. Some agents commonly used to treat nausea, such as metoclopramide, are listed as potentially interacting with Bromergon.


Q: Do I need to get blood tests while I am taking Bromergon?

Regulatory documents state that routine monitoring is necessary, particularly blood pressure checks, especially during the initial phase of treatment. Depending on the condition, periodic cardiac assessment and hormone monitoring may also be required.


Q: What happens if I accidentally take more Bromergon than prescribed?

No specific overdose protocol is detailed in patient information. However, in case of severe symptoms, such as sudden weakness, seizures, or chest pain, immediate emergency medical attention is advised.

How should Bromergon be stored and disposed of?

Bromergon (bromocriptine mesylate) must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness.


Storage Conditions

Requirement Details
Temperature Must be stored at a Controlled Room Temperature of 20°C to 25°C (68°F to 77°F).
Protection Keep the medicine protected from light, moisture, and heat. Do not freeze.
Container Store in the original container, ensuring it remains tightly closed and uses a child-resistant closure.

Handling and Disposal

Bromergon must always be stored out of the sight and reach of children to prevent accidental ingestion. When the product is expired or no longer needed, it should not be disposed of in household trash or poured down a drain. Disposal of unused product must be done in accordance with local regulations, often by utilizing a medication take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bromergon found in:

A-Z Index: